20 Preclinical studies have demonstrated avapritinib's efficacy in inhibiting tumor growth and reducing angiogenesis in NSCLC models expressing PDGFRA D842V and KIT exon 17 D816V mutations. Here, PDGFRA is linked to non-small cell lung carcinoma.